Abstract
Only a small proportion of COVID-19 patients in Canada have been recruited into clinical research studies. One reason is that few community intensive care units (ICUs) in Canada participate in research. The objective of this study was to examine the motivating factors, barriers and facilitators to research participation amongst Canadian community ICU stakeholders. A cross-sectional online survey was distributed between May and November 2020. The survey focused on 6 domains: participant demographics, ICU characteristics, ICU research infrastructure, motivating factors, perceived barriers, and perceived facilitators. Responses were received from 73 community ICU stakeholders, representing 18 ICUs. 7/18 ICUs had a clinical research program. Participants rated their interest in pandemic research at a mean of 5.2 (Standard Deviation [SD] = 1.9) on a 7-point Likert scale from ‘not interested’ to ‘very interested’. The strongest motivating factor for research participation was the belief that research improves clinical care and outcomes. The most significant facilitators of research involvement were the availability of an experienced research coordinator and dedicated external funding to cover start-up costs, while the most significant barriers to research involvement were a lack of start-up funding for a research coordinator and a lack of ICU research experience. Canadian Community ICU stakeholders are interested in participating in pandemic research but lack basic infrastructure, research personnel, research experience and start-up funding. Evolution of a research support model at community hospitals, where most patients receive acute care, may increase research participation and improve the generalizability of funded research in Canada.
Funder
Canadian Critical Care Trials Group
Publisher
Public Library of Science (PLoS)
Reference16 articles.
1. Government of Canada. (2022, Feb 10). COVID-19 Daily Epidemiology Update. Canada.ca. Retrieved February 10, 2022, from https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html
2. Dexamethasone in Hospitalized Patients with Covid-19;The RECOVERY Collaborative Group;New England Journal of Medicine,2021
3. Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial;The Writing Committee for the REMAP-CAP Investigators;JAMA,2020
4. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19;The REMAP-CAP Investigators;New England Journal of Medicine,2021
5. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study;R. Challen;BMJ,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献